A NEW strain of the mpox virus has been detected in the UK, and now an expert has warned not to confuse the symptoms with ...

New data show tolerability and no evidence of spreading to blood or tissues even at high doses of Tonix’s attenuated live-virus, minimally ...

Guggenheim last night initiated coverage of Genelux (GNLX) with a Buy rating and $8 price target Genelux is a clinical-stage Biotech company ...

The Foreign, Commonwealth and Development Office (FCDO) shared the latest health information for the European Union country.

KaliVir is at the forefront of developing novel cancer therapies using its proprietary Vaccinia Enhanced Template (VET™) platform. This platform allows for the expression and systemic delivery ...

The Phase II trial seeks to further validate the potential of Olvi-Vec in resensitising patients to platinum therapies across ...

(GLOBE NEWSWIRE) -- (NASDAQ: GNLX), a late-stage clinical immuno-oncology company, today announced that the first patient has been dosed in the U.S.-based Phase 2 (VIRO-25) trial evaluating ...

The modified vaccinia Ankara-Bavarian Nordic mpox vaccine (MVA-BN; Jynneos) generated robust immune responses in adolescents ...

The VIRO-25 clinical trial (NCT06463665), is an open-label, randomized study in NSCLC designed to evaluate the efficacy and safety of an intravenously delivered oncolytic vaccinia virus, Olvi-Vec, ...

The MVA-MERS-S vaccine candidate developed at the German Center for Infection Research (DZIF) since 2013 is based on an attenuated virus—the so-called "Modified Vaccinia Ankara Virus" (MVA ...

MpoxVax AFRIVAC (Expanding a prospective, clinical trial examining the immune response of participants receiving Modified Vaccinia Ankara vaccine to Africa) will expand a trial exploring the ...